公开(公告)号：EP1372164B1

公开(公告)日：2007-10-17

申请号：EP03013150.2

申请日：2003-06-11

申请人： International Superconductivity Technology Center, The Juridical Foundation ,  Railway Technical Research Institute, The Juridical Foundation

发明人： Tomita, Masaru, Superconductivity Research Lab. ,  Murakami, Masato, Superconductivity Research Lab.

IPC分类号： H01F6/00 ,  H01L39/24 ,  H01L39/12

CPC分类号： H01L39/126 ,  H01F6/00 ,  H01L39/2464 ,  Y10T29/49014

公开(公告)号：EP1712918B1

公开(公告)日：2012-06-20

申请号：EP04807583.2

申请日：2004-12-22

申请人： Mitsubishi Chemical Medience Corporation ,  Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： ONO, Tomoko ,  SOEJIMA, Kenji ,  HIRASHIMA, Masaki ,  MORIKAWA, Wataru ,  SAKATA, Yoichi

IPC分类号： G01N33/573

CPC分类号： G01N33/6893 ,  G01N2333/95 ,  G01N2800/222 ,  G01N2800/226 ,  G01N2800/32 ,  Y10S436/811 ,  Y10T436/106664

摘要： A method of detecting the level of thrombus formation tendency or thrombosis through determining of the quantity of von Willebrand factor splitting enzyme. There is further disclosed a kit for detecting the level of thrombus formation tendency or thrombosis, which kit includes an antibody capable of specific binding to von Willebrand factor splitting enzyme, or a fragment of the antibody. The provided detection method and detection kit excel in convenience, speed and specificity.

公开(公告)号：EP2374878A3

公开(公告)日：2012-05-30

申请号：EP11003287.7

申请日：2008-06-19

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： Soejima, Kenji

IPC分类号： C12N9/64 ,  A61K38/00 ,  A61P7/02 ,  A61P43/00 ,  C12N15/09

CPC分类号： C12N9/6489 ,  A61K38/00 ,  A61K38/4886 ,  C12Y304/24087

摘要： The present invention provides a method of enhancing an enzymatic activity of ADAMTS-13 and/or a method of reducing reactivity to an anti-ADAMTS-13 neutralizing antibody as well as a mutant of ADAMTS-13 prepared by the methods. The method of the present invention is characterized by substituting at least one charged amino acid in a disintegrin-like domain, a cysteine-rich domain or a spacer domain of ADAMTS-13 other than the following amino acids with a different amino acid: arginine at position 326, aspartic acid at position 330, aspartic acid at position 343 and arginine at position 349 in the disintegrin-like domain, aspartic acid at position 480, arginine at position 488, arginine at position 498, arginine at position 507, aspartic acid at position 533 and aspartic acid at position 543 in the cysteine-rich domain, and glutamic acid at position 641 and arginine at position 660 in the spacer domain. The present invention also provides a therapeutic agent for thrombotic disease comprising as an active ingredient the mutant of ADAMTS-13 prepared by the method.

公开(公告)号：EP2395026A2

公开(公告)日：2011-12-14

申请号：EP11179903.7

申请日：2006-02-07

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： Torikai, Masaharu ,  Nakashima, Toshihiro

IPC分类号： C07K16/46 ,  C07K16/00 ,  C07K16/12 ,  C07K16/28 ,  A61K39/395

CPC分类号： C07K16/00 ,  C07K16/1271 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/94

摘要： The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying a human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as "VL chain") of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.

摘要翻译： 本发明提供了改善抗体性质的方法，例如表达水平和稳定性。 通过修饰人抗体或人源化抗体获得具有改善的表达水平和/或稳定性的抗体的方法，其特征在于，第8,12,15或18位的氨基酸残基中的至少任一种（根据Kabat 编号）在人抗体或人源化抗体的轻链可变区（以下称为“VL链”）中被除脯氨酸或半胱氨酸以外的不同氨基酸，人抗体或人源化抗体或人 抗体片段或具有通过所述方法获得的改善的表达水平和/或稳定性的人源化抗体片段。

公开(公告)号：EP1310584B1

公开(公告)日：2011-11-16

申请号：EP02728094.0

申请日：2002-05-21

申请人： International Superconductivity Technology Center, The Juridical Foundation

发明人： LEE, Sergey, Romanovich ,  YAMAMOTO, Ayako ,  TAJIMA, Setsuko

IPC分类号： C30B29/10 ,  C01B35/04

CPC分类号： C01B35/04 ,  B01J3/062 ,  B01J2203/0605 ,  B01J2203/0645 ,  B01J2203/068 ,  Y10T29/49014 ,  Y10T29/49117

摘要： Means for producing an MgB2 single crystal and a useful superconductive material using the anisotropic superconductive characteristics thereof. A mixture material of Mg and B or a precursor containing MgB2 microcrystals produced by reacting them is brought into contact with hexagonal crystal BN, and they are held at high temperature (1300 ° C to 1700 ° C) under high pressure (3 to 6 GPa) so as to grow anisotropic MgB2 single crystals having superconductive properties through intermediate products. The single crystal has a feature that the irreversible magnetic field is 95% or more of the second critical magnetic field depending on the direction of the applied magnetic field, and therefore can be a superconductive material having excellent characteristics by adjusting the crystal orientation. It is advantageous for single crystal growth to be coexistent with a reducer such as Mg during the reaction or by establishing a temperature gradient in the melt.

公开(公告)号：EP1956093B1

公开(公告)日：2011-09-21

申请号：EP08156811.5

申请日：2002-04-25

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： Soejima, Kenji ,  Mimura, Noriko ,  Maeda, Hiroaki ,  Nozaki, Chikateru ,  Hamamoto, Takayoshi ,  Nakagaki, Tomohiro

IPC分类号： C12N15/57 ,  C12N9/50 ,  C12P21/00

CPC分类号： C12N9/6489 ,  A61K31/711 ,  A61K38/00 ,  C12N9/50 ,  C12N9/6421

公开(公告)号：EP2360701A1

公开(公告)日：2011-08-24

申请号：EP09827604.1

申请日：2009-11-19

申请人： International Superconductivity Technology Center, The Juridical Foundation ,  The Furukawa Electric Co., Ltd. ,  Japan Fine Ceramics Center

发明人： MIYATA, Seiki ,  FUKUSHIMA, Hiroyuki ,  KURIKI, Reiji ,  IBI, Akira ,  YOSHIZUMI, Masateru ,  KINOSHITA, Akio ,  YAMADA, Yutaka ,  SHIOHARA, Yuh ,  YOSHIDA, Ryuji ,  KATO, Takeharu ,  HIRAYAMA, Tsukasa

IPC分类号： H01B12/06 ,  C01G1/00 ,  C01G3/00 ,  C22C19/03 ,  H01B13/00

CPC分类号： H01L39/2461 ,  Y10T428/24355

摘要： Provided is a substrate for superconductive film formation, which includes a metal substrate, and an oxide layer formed directly on the metal substrate, containing chromium oxide as a major component and having a thickness of 10-300 nm and an arithmetic average roughness Ra of not more than 50 nm. A method of manufacturing a substrate for superconductive film formation, which includes forming an oxide layer directly on a metal substrate, the oxide layer containing chromium oxide as a major component and having a thickness of 10-300 nm and an arithmetic average roughness Ra of not more than 50 nm.

摘要翻译： 本发明提供一种超导膜形成，其包括金属基底，并在金属基底上直接形成氧化物层上，含铬氧化物作为主要组分，并且具有的厚度为10-300纳米，以不算术平均粗糙度Ra一个基板 超过50nm。制造用于超导膜形成，其包括在金属基板氧化物层上形成直接，氧化物层含铬氧化物作为主要成分的基片和具有算术的厚度为10-300纳米，的方法 不超过50纳米的平均粗糙度Ra。

公开(公告)号：EP2243829A1

公开(公告)日：2010-10-27

申请号：EP09700904.7

申请日：2009-01-09

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ,  Astellas Pharma Inc.

发明人： UEHARA, Kenji ,  HIGUCHI, Hirofumi ,  NAKASHIMA, Toshihiro ,  ISHIKAWA, Daisuke ,  YAMAMOTO, Nobuchika ,  FUJITA, Hirotada ,  SAKAI, Fumihiko

IPC分类号： C12N15/00 ,  A61K39/395 ,  A61P29/00 ,  C07K16/28 ,  C07K16/46 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/08

CPC分类号： C07K16/2839 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.

摘要翻译： 本发明提供与供体小鼠抗人±9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人±9整联蛋白抗体，即含有重链的人源化抗人±9整联蛋白抗体 由SEQ ID NO：11所示的氨基酸序列组成的可变区和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，包含重链的人源化抗人±9整联蛋白抗体 由SEQ ID NO：13所示的氨基酸序列组成的可变区和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，包含重链的人源化抗人±9整联蛋白抗体 由SEQ ID NO：15所示的氨基酸序列组成的可变区和由SEQ ID NO：9所示的氨基酸序列组成的轻链可变区，以及预防或治疗涉及人类± 9整数 rin在发病机制中，其使用抗体。

公开(公告)号：EP1394112B1

公开(公告)日：2010-10-20

申请号：EP02724762.6

申请日：2002-05-10

申请人： International Superconductivity Technology Center, The Juridical Foundation

发明人： ZHAO, Yong, ,  FENG, Yong, ,  WU, Yuan, ,  MACHI, Takato, ,  FUDAMOTO, Yasunori, ,  KOSHIZUKA, Naoki, ,  MURAKAMI, Masato,

IPC分类号： C04B35/63 ,  C04B35/58 ,  H01L39/12 ,  H01L39/24

CPC分类号： H01L39/125 ,  C04B35/58057 ,  C04B35/6303 ,  C04B2235/3813 ,  C04B2235/401 ,  C04B2235/404 ,  C04B2235/421 ,  C04B2235/5436 ,  C04B2235/80 ,  C04B2235/94 ,  H01L39/2487 ,  Y10S420/901 ,  Y10S428/93

公开(公告)号：EP2202306A1

公开(公告)日：2010-06-30

申请号：EP08837781.7

申请日：2008-10-08

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： SOEJIMA, Kenji ,  IMAMURA, Takayuki ,  KAWAMURA, Ryoichi ,  NAKATAKE, Hiroshi ,  MAEYASHIKI, Arisa ,  TOGO, Hitomi

IPC分类号： C12N15/09 ,  A61K38/43 ,  A61P7/04 ,  C07K14/745 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02

CPC分类号： C12N9/6432 ,  A61K38/00 ,  C12Y304/21006

摘要： A Factor X (hereinafter referred to as "FX") with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.

摘要翻译： 提供了具有高活性的因子X（以下称为“FX”）。 本发明涉及一种有效制备重组双链FX的方法，该方法包括在FX中糖基化所必需的氨基酸序列上插入糖基化，从而允许没有糖基化的重组FX的表达， 通过所述方法获得的没有糖基化的FX。